WT1 W10

Drug Profile

WT1 W10

Alternative Names: WT1 W10

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator NEC Corporation
  • Developer Kochi University; NEC Corporation
  • Class Antineoplastics; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes
  • Phase I Glioblastoma
  • Clinical Phase Unknown Pancreatic cancer

Most Recent Events

  • 08 Feb 2017 NEC Corporation and Kochi University suspend a clinical trial in Pancreatic cancer (Second-line therapy or greater, Adjunctive therapy) in Japan before February 2017 (UMIN000026049)
  • 05 Jan 2017 Phase-I clinical trials in Glioblastoma (Combination therapy) in Japan (Intradermal) (UMIN000025452)
  • 01 May 2016 Clinical trials in Pancreatic cancer (Second-line therapy or greater, Adjunctive treatment) in Japan (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top